POMDOCTOR Partners with Pharma Firms to Accelerate Internet Hospital Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: Newsfilter
- Significant Market Potential: According to Yaozh.com, China's online pharmaceutical sales market has surged from approximately RMB 19 billion in 2020 to about RMB 60.8 billion in 2023, with projections of reaching RMB 71.8 billion (approximately $10.3 billion) in 2024, reflecting a remarkable CAGR of 39.4%, indicating vast growth opportunities.
- Deepening Strategic Collaborations: POMDOCTOR has entered into sales agreements with several publicly listed pharmaceutical companies, including Jiangsu Haosoh and Xiamen Amoytop, enabling the introduction of innovative drugs on its internet hospital platforms, thereby enhancing treatment options for patients and providing efficient sales channels for pharmaceutical firms.
- Favorable Procurement Mechanism: Under the agreements, POMDOCTOR is entitled to purchase discounts and sales incentives upon achieving specific sales targets, which not only boosts the company's profitability but also offers attractive market entry strategies for its pharmaceutical partners.
- Innovative Supply Chain Model: POMDOCTOR's flexible collaboration model reduces intermediaries while enhancing transparency and accessibility, driving the evolution of modern pharmaceutical distribution, and is expected to provide patients and pharmacies with more competitive pricing and stable supply.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
